Leerink Swann Downgrades MAP Pharmaceuticals (MAPP) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Deutsche Bank Downgrades MAP Pharmaceuticals (MAPP) to Hold; Doesn't Expect Other Bids
January 28, 2013 9:02 AM ESTDeutsche Bank downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold following takeover deal. The firm doesn't expect other bids.
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For... More
Canaccord Genuity Downgrades MAP Pharmaceuticals (MAPP) to Hold
January 24, 2013 8:43 AM ESTCanaccord Genuity downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold with a price target of $25 on of Allergan takeover.
"Were still surprised by the timing though more may be known when filings come out. At this point we think the... More
Allergan (AGN) Acquires MAP Pharmaceuticals (MAPP) for $958M
January 23, 2013 6:34 AM ESTAllergan, Inc. (NYSE: AGN) agreed to acquire MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) for $25 per share, or approximately $958 million. The offer represents a 60% premium over MAPs closing stock price on the Nasdaq Stock Market of $15.58 on January 22, 2013.
The acquisition is expected to close late in the first quarter or in the second quarter of 2013.
In January 2011, Allergan entered into... More
